Glaukos Corp
NYSE:GKOS

Watchlist Manager
Glaukos Corp Logo
Glaukos Corp
NYSE:GKOS
Watchlist
Price: 112.72 USD 1.82% Market Closed
Updated: Jun 2, 2024

Intrinsic Value

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. [ Read More ]

The intrinsic value of one GKOS stock under the Base Case scenario is hidden USD. Compared to the current market price of 112.72 USD, Glaukos Corp is hidden .

Key Points:
GKOS Intrinsic Value
HIDDEN
Unlock
Base Case Scenario

Valuation Backtest
Glaukos Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GKOS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Ask me anything about
Glaukos Corp

Provide an overview of the primary business activities
of Glaukos Corp.

What unique competitive advantages
does Glaukos Corp hold over its rivals?

What risks and challenges
does Glaukos Corp face in the near future?

Has there been any significant insider trading activity
in Glaukos Corp recently?

Summarize the latest earnings call
of Glaukos Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Glaukos Corp.

Provide P/S
for Glaukos Corp.

Provide P/E
for Glaukos Corp.

Provide P/OCF
for Glaukos Corp.

Provide P/FCFE
for Glaukos Corp.

Provide P/B
for Glaukos Corp.

Provide EV/S
for Glaukos Corp.

Provide EV/GP
for Glaukos Corp.

Provide EV/EBITDA
for Glaukos Corp.

Provide EV/EBIT
for Glaukos Corp.

Provide EV/OCF
for Glaukos Corp.

Provide EV/FCFF
for Glaukos Corp.

Provide EV/IC
for Glaukos Corp.

Show me price targets
for Glaukos Corp made by professional analysts.

What are the Revenue projections
for Glaukos Corp?

How accurate were the past Revenue estimates
for Glaukos Corp?

What are the Net Income projections
for Glaukos Corp?

How accurate were the past Net Income estimates
for Glaukos Corp?

What are the EPS projections
for Glaukos Corp?

How accurate were the past EPS estimates
for Glaukos Corp?

What are the EBIT projections
for Glaukos Corp?

How accurate were the past EBIT estimates
for Glaukos Corp?

Compare the revenue forecasts
for Glaukos Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Glaukos Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Glaukos Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Glaukos Corp compared to its peers.

Compare the P/E ratios
of Glaukos Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Glaukos Corp with its peers.

Analyze the financial leverage
of Glaukos Corp compared to its main competitors.

Show all profitability ratios
for Glaukos Corp.

Provide ROE
for Glaukos Corp.

Provide ROA
for Glaukos Corp.

Provide ROIC
for Glaukos Corp.

Provide ROCE
for Glaukos Corp.

Provide Gross Margin
for Glaukos Corp.

Provide Operating Margin
for Glaukos Corp.

Provide Net Margin
for Glaukos Corp.

Provide FCF Margin
for Glaukos Corp.

Show all solvency ratios
for Glaukos Corp.

Provide D/E Ratio
for Glaukos Corp.

Provide D/A Ratio
for Glaukos Corp.

Provide Interest Coverage Ratio
for Glaukos Corp.

Provide Altman Z-Score Ratio
for Glaukos Corp.

Provide Quick Ratio
for Glaukos Corp.

Provide Current Ratio
for Glaukos Corp.

Provide Cash Ratio
for Glaukos Corp.

What is the historical Revenue growth
over the last 5 years for Glaukos Corp?

What is the historical Net Income growth
over the last 5 years for Glaukos Corp?

What is the current Free Cash Flow
of Glaukos Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Glaukos Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Glaukos Corp

Current Assets 388.6m
Cash & Short-Term Investments 272.9m
Receivables 46.5m
Other Current Assets 69.2m
Non-Current Assets 544.7m
PP&E 172.1m
Intangibles 348.1m
Other Non-Current Assets 24.6m
Current Liabilities 72.2m
Accounts Payable 12.8m
Accrued Liabilities 59.5m
Non-Current Liabilities 410.4m
Long-Term Debt 353.4m
Other Non-Current Liabilities 57m
Efficiency

Earnings Waterfall
Glaukos Corp

Revenue
326.4m USD
Cost of Revenue
-77.8m USD
Gross Profit
248.7m USD
Operating Expenses
-369.7m USD
Operating Income
-121m USD
Other Expenses
-19.8m USD
Net Income
-140.9m USD

Free Cash Flow Analysis
Glaukos Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GKOS Profitability Score
Profitability Due Diligence

Glaukos Corp's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
hidden
Profitability
Score

Glaukos Corp's profitability score is hidden . The higher the profitability score, the more profitable the company is.

GKOS Solvency Score
Solvency Due Diligence

Glaukos Corp's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
hidden
Solvency
Score

Glaukos Corp's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GKOS Price Targets Summary
Glaukos Corp

Wall Street analysts forecast GKOS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GKOS is 115.91 USD with a low forecast of 101 USD and a high forecast of 136.5 USD.

Lowest
Price Target
101 USD
10% Downside
Average
Price Target
115.91 USD
3% Upside
Highest
Price Target
136.5 USD
21% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GKOS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GKOS Price
Glaukos Corp

1M 1M
+7%
6M 6M
+73%
1Y 1Y
+81%
3Y 3Y
+53%
5Y 5Y
+77%
10Y 10Y
+526%
Annual Price Range
112.72
52w Low
59.53
52w High
112.72
Price Metrics
Average Annual Return -6.29%
Standard Deviation of Annual Returns 26.06%
Max Drawdown -70%
Shares Statistics
Market Capitalization 5.6B USD
Shares Outstanding 50 367 500
Percentage of Shares Shorted 11.86%

GKOS Return Decomposition
Main factors of price return

What is price return decomposition?

GKOS News

Other Videos

Company Profile

Glaukos Corp Logo
Glaukos Corp

Country

United States of America

Industry

Health Care

Market Cap

5.6B USD

Dividend Yield

0%

Description

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company is headquartered in San Clemente, California and currently employs 727 full-time employees. The company went IPO on 2015-06-25. The company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.

Contact

CALIFORNIA
San Clemente
229 Avenida Fabricante
+19493679600.0
https://www.glaukos.com

IPO

2015-06-25

Employees

727

Officers

Chairman & CEO
Mr. Thomas William Burns
President & COO
Mr. Joseph E. Gilliam
Senior VP & CFO
Mr. Alex R. Thurman
Executive Vice President of Global Commercial Operations
Mr. Chris M. Calcaterra
Chief Development Officer
Dr. Tomas Navratil Ph.D.
Co-Founder
Dr. Mory Gharib Ph.D.
Show More
Vice President of Investor Relations & Corporate Affairs
Mr. Christopher William Lewis
VP of Compliance & Deputy General Counsel
Ms. Diana A. Scherer
Senior Vice President of Human Resources
Ms. Michele M. Allegretto
Senior Vice President of Corporate Strategy & Business Development
Ms. Jane E. Rady
Show Less

See Also

Discover More
What is the Intrinsic Value of one GKOS stock?

The intrinsic value of one GKOS stock under the Base Case scenario is hidden USD.

Is GKOS stock undervalued or overvalued?

Compared to the current market price of 112.72 USD, Glaukos Corp is hidden .